Calamos Advisors’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Calamos Advisors’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-125,000	Closed	-$1.36K	–	1294
2022 Q4	$1.36K	Hold	125,000	–	–	﹤0.01%	1204
2022 Q3	$12K	Buy	+125,000	New	+$13.4K	﹤0.01%	1160

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Calamos Advisors's IBER.WS Position: Q1 2023 in Review

Calamos Advisors sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 125,000 shares — an estimated $1.36K sold.

Calamos Advisors first reported a position in IBER.WS in Q3 2022 and held it in 2 quarters. The position peaked at $12K in Q3 2022. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Calamos Advisors reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Calamos Advisors sold 125,000 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $1.36K.
Calamos Advisors first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q3 2022 and held it in 2 quarters.
Calamos Advisors's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $12K in Q3 2022.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.